MetaCap

BrainsWay (BWAY) vs Embecta (EMBC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BrainsWay (BWAY) has outperformed Embecta (EMBC) over the past year, gaining 13.9% versus a loss of 58.7%. BrainsWay is the larger company by market cap ($341.3 million vs $341.1 million), about 1.0 times the size. On valuation, Embecta trades at a lower forward P/E (3.4x vs 17.0x for BrainsWay).

Embecta pays a dividend yielding 7.64%, while BrainsWay does not currently pay one. Embecta converts more of its revenue into profit, with a net margin of 8.8% versus 7.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BWAY+13.90%EMBC-58.68%
+141%+25%-91%
Nov 21, 20251 yearNov 20, 2026
BWAY+100.00%EMBC-86.00%
+325%+106%-113%
Mar 21, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BWAY versus EMBC key metrics
MetricBWAYEMBC
Share price$8.48$6.02
Market cap$341.35M$341.09M
1-day change-2.86%-2.75%
YTD return-10.83%-49.33%
1-year return+13.90%-58.68%
5-year return+130.75%—
P/E ratio (TTM)35.334.10
Forward P/E16.963.42
EPS (TTM)$0.24$1.47
Dividend yield0.00%7.64%
Annual dividend$0.00$0.46
Revenue (latest FY)$41.02M$1.08B
Revenue growth (YoY)+29.04%-3.80%
Net income (latest FY)$2.92M$95.40M
Gross margin74.56%62.64%
Operating margin3.39%22.41%
Net margin7.12%8.83%
52-week high$17.40$14.78
52-week low$7.30$2.77
Distance from 52-week high-51.26%-59.27%
Analyst consensusstrong_buynone
Avg. price target upside+127.24%-33.55%
Average volume110.35K1.01M
Shares outstanding40.25M56.66M
Employees1291,850
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BWAY has outperformed EMBC by 72.6 percentage points over the past year.
  • BrainsWay trades at a higher earnings multiple (35.3x vs 4.1x trailing P/E).
  • Embecta offers a meaningfully higher dividend yield (7.64% vs 0.00%).
  • BrainsWay grew revenue faster in its latest fiscal year (+29.04% vs -3.80%).

About BrainsWay

BWAY stock →

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally.

Health Care · Medical/Dental Instruments · 129 employees

About Embecta

EMBC stock →

Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.

Health Care · Medical/Dental Instruments · 1,850 employees

BWAY vs EMBC FAQ

Which is bigger, BrainsWay or Embecta?

BrainsWay (BWAY) is larger, with a market capitalization of $341.35M compared with $341.09M for Embecta (EMBC).

Which stock has performed better over the past year, BWAY or EMBC?

BWAY returned +13.90% over the past 12 months, compared with -58.68% for EMBC (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, BWAY or EMBC?

EMBC has the lower trailing P/E at 4.1, versus 35.3 for BWAY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, BrainsWay or Embecta?

Embecta pays a dividend yielding 7.64%, while BrainsWay does not currently pay a regular dividend.

Are BrainsWay and Embecta in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons